Investors / United States / MVM Partners
MVM Partners
Venture capital · Boston, MA, United States · North America
MVM Partners is a healthcare investment firm that has invested in high growth healthcare businesses since 1997. It provides equity to companies and works with management teams to bring products to market, drive growth, and make strategic acquisitions.
Invests inHealthcare & Biotech
In its own wordshealthcaremedical devicespharmaceuticalsdiagnosticsdigital healthlife science tools
Your fit with MVM Partners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsMVM Partners lists 10 checked portfolio companies on its own site and is named in 5 funding rounds, 3 of them as lead. Its most frequent entry is Growth, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 67% of its companies are based in United States. It invests most often alongside Advent Life Sciences, Aisling Capital and Aperture Venture Partners.
Counts come from funding rounds that name MVM Partners, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not MVM Partners' whole history. Rounds on record name 4 companies; its own site lists 10. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundMVM Partners does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 25% |
| Series B | 25% |
| Growth | 50% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 3 | 2 |
| '26 | 2 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 23th | 10 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 97th | 30% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 70th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Advent Life Sciences | 1 |
| Aisling Capital | 1 |
| Aperture Venture Partners | 1 |
| Asahi Kasei Ventures | 1 |
| Atlantic Bridge | 1 |
| B Capital | 1 |
| Claret Capital Partners | 1 |
| Decheng Capital | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers880%
- No longer answers00%
- Points to another company220%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Advent Life Sciences
Compare MVM Partners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with MVM Partners| Date | Company | Stage |
|---|---|---|
| 9 Jun 2026 | Series C+ | |
| 11 Feb 2026 | Series C+ Led | |
| 18 Nov 2025 | Series A Led | |
| 26 Aug 2025 | Series B Led | |
| 15 Jul 2025 | Series C+ |
Round details for MVM Partners
Amounts, full round histories and every co-investor in MVM Partners' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
10 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| AmbioPharm provides peptide manufacturing and development services for pharmaceutical and biotech companies. | Healthcare & Biotech | Portfolio page | ||
| Avanzanite Bioscience B.V. expands patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical partners. | Healthcare & Biotech | Nov 2025Series A | Funding round | |
| The company develops a balloon implant system used to protect healthy tissue from radiation during oncology treatments. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Jul 2025Series C+ · 2 rounds | Page + round | ||
| Nalu provides instructions and support for its neurostimulation system | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Feb 2026Series C+ | Page + round | ||
| Olympus Corporation develops and manufactures medical and scientific products, including endoscopes and other medical devices. | Healthcare & Biotech | Portfolio page | ||
| Optinose is a specialty pharmaceutical company focused on creating and bringing to market innovative products for patients with diseases treated by ear, nose, and throat (ENT) and allergy specialists. | Healthcare & Biotech | Portfolio page | ||
| Paratek Pharmaceuticals develops and commercializes new treatment options for complex medical issues, including infectious diseases and chronic rhinosinusitis. | Healthcare & Biotech | Portfolio page | ||
| Proverum Medical develops and manufactures a stent system to alleviate Lower Urinary Tract Symptoms caused by an enlarged prostate. | Healthcare & Biotech | Aug 2025Series B | Page + round |
About this data
site last read 8 Nov 2026- Site
- mvm.com
- Last read
- 8 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 15 Jul 2025
- Companies checked
- 10
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get MVM Partners' profile as data
Pull MVM Partners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/mvm.com
# also
GET /v1/firms/mvm.com/portfolio
GET /v1/firms/mvm.com/coinvestors
GET /v1/firms/mvm.com/news